Abstract
Oestrogen receptor positive (ER+) breast cancers are susceptible to endocrine treatments, such as tamoxifen. However, resistance is a major problem when treating breast cancer with these agents. ERα phosphorylation is implicated in this resistance to tamoxifen, and kinases are the enzymes that catalyse phosphorylation. A kinome search in human breast cancer cells identified lemur tyrosine kinase 3 (LMTK3). In primary breast cancer samples, high nuclear LMTK3 expression was associated with a shorter disease-free survival time. In tamoxifen-resistant cell lines, the addition of LMTK3 siRNA, increased the inhibitory effect of tamoxifen. In nude mice, with established human MCF-7 breast cancer tumours, LMTK3 siRNA decreased tumour growth. In conclusion, LMKT3 is a possible target and marker of breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
